Kidney Cancer Tissue Bank and Data Repository Core
Official title: DF/HCC Kidney Cancer Tissue, Acquisition, Pathology and Clinical Data Core 2
Funded at Beth Israel Deaconess Medical Center · NIH-11421797 · Data updated 2026-11-12
A kidney cancer tissue, blood and clinical data repository core aims to collect, store, and organize samples and linked clinical information to support research and improve care for kidney cancer patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 18, 2003 |
| Project end | August 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $322,234 |
| NIH project number | 2P50CA101942-21A1 |
| Project ID | NIH-11421797 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with kidney cancer who consent to linking their tissue and clinical data to the repository are ideal contributors.
✕Less likely to help
Patients who do not wish to donate samples or share their data may not directly benefit from this core.
What this research studies
This core collects fresh kidney tumor tissue, paired non-tumor tissue, blood, and urine from consenting patients, and stores them with linked clinical data. It uses tissue microarrays and standardized pathology reviews to ensure high-quality samples for research. The TAPCD Core also maintains a database of clinical data and tracks specimens with barcode-based inventory systems to facilitate access for approved researchers. Through collaboration among DF/HCC hospitals, the core supports researchers in studying kidney cancer biology and developing better diagnostics and treatments.
Why it matters
Potential benefit: If successful, this core can accelerate kidney cancer discoveries by providing well-annotated, high-quality biospecimens and data to researchers and clinicians.
How similar studies have gone: Similar biospecimen banks with linked clinical data have advanced kidney cancer research and biomarker discovery in prior work.
Where this research is happening
-
Beth Israel Deaconess Medical Center
Boston, United States Active
Researchers
- Principal investigator: Einstein, David J. — Beth Israel Deaconess Medical Center
- Study coordinator: Einstein, David J.
Related research
Other NIH-funded projects on the same topics.
-
Maximizing anti-tumor immune responses in kidney cancer
A cutting-edge program at UT Southwestern aims to speed up better immunotherapy options for kidney cancer by studying how to activate both innate and adaptive immune responses.
-
Kidney Cancer Career Enhancement Program (CEP) at DF/HCC
A career-boosting program supports junior investigators studying kidney cancer to help them advance in basic, translational, and clinical work.
-
Kidney Cancer Development Program at DF/HCC
A funded program at Dana-Farber/Brigham and Women’s Kidney Cancer Center supports new ideas from researchers to improve understanding and treatment of kidney cancer.
-
Personalized antigens for kidney cancer therapy
This grant explores identifying and targeting tumor-specific antigens in kidney cancer to develop more effective, personalized immunotherapies.
-
Optimizing Anti-PD1 Therapy for High-Risk and Metastatic Kidney Cancer
A large cancer research grant is testing how best to use anti-PD-1 therapy to help people with high-risk and metastatic kidney cancer live longer and with fewer side effects.
-
Targeting the HIF2 Pathway in Kidney Cancer
A cancer treatment program aims to see if a drug called belzutifan can help people with a specific kind of kidney cancer whose growth is driven by the HIF2 pathway.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.